Minimal alveolar concentration of sevoflurane in end-stage liver disease patients undergoing liver transplantation

Phase 4, open-label trial of sevoflurane in hepatic failure, Cirrhosis and liver transplant (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Minimal alveolar concentration (MAC) of sevoflurane in end-stage liver disease patients undergoing orthotopic liver transplantation. Started May 2014; status: completed.